Last reviewed · How we verify
raltegravir and atazanavir and ritonavir
raltegravir and atazanavir and ritonavir is a Antiretroviral combination therapy (INSTI + PI + booster) Small molecule drug developed by Giovanni Di Perri. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced patients. Also known as: Isentress (raltegravir), Reyataz (atazanavir), Norvir (ritonavir).
This is a three-drug antiretroviral combination that inhibits HIV replication through complementary mechanisms: raltegravir blocks HIV integrase, while atazanavir and ritonavir inhibit HIV protease.
This is a three-drug antiretroviral combination that inhibits HIV replication through complementary mechanisms: raltegravir blocks HIV integrase, while atazanavir and ritonavir inhibit HIV protease. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | raltegravir and atazanavir and ritonavir |
|---|---|
| Also known as | Isentress (raltegravir), Reyataz (atazanavir), Norvir (ritonavir) |
| Sponsor | Giovanni Di Perri |
| Drug class | Antiretroviral combination therapy (INSTI + PI + booster) |
| Target | HIV integrase, HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Raltegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV DNA from integrating into the host genome. Atazanavir is a protease inhibitor that blocks the HIV protease enzyme needed to process viral proteins, and ritonavir is a pharmacokinetic booster that inhibits CYP3A4 metabolism, increasing atazanavir levels. Together, these agents target different stages of the HIV replication cycle.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Nausea
- Diarrhea
- Headache
- Hyperbilirubinemia
- Rash
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Population Pharmacokinetics of Antiretroviral in Children
- Kuwa Free! - Live Free! (NA)
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
- IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- raltegravir and atazanavir and ritonavir CI brief — competitive landscape report
- raltegravir and atazanavir and ritonavir updates RSS · CI watch RSS
- Giovanni Di Perri portfolio CI
Frequently asked questions about raltegravir and atazanavir and ritonavir
What is raltegravir and atazanavir and ritonavir?
How does raltegravir and atazanavir and ritonavir work?
What is raltegravir and atazanavir and ritonavir used for?
Who makes raltegravir and atazanavir and ritonavir?
Is raltegravir and atazanavir and ritonavir also known as anything else?
What drug class is raltegravir and atazanavir and ritonavir in?
What development phase is raltegravir and atazanavir and ritonavir in?
What are the side effects of raltegravir and atazanavir and ritonavir?
What does raltegravir and atazanavir and ritonavir target?
Related
- Drug class: All Antiretroviral combination therapy (INSTI + PI + booster) drugs
- Target: All drugs targeting HIV integrase, HIV protease
- Manufacturer: Giovanni Di Perri — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced patients
- Also known as: Isentress (raltegravir), Reyataz (atazanavir), Norvir (ritonavir)
- Compare: raltegravir and atazanavir and ritonavir vs similar drugs
- Pricing: raltegravir and atazanavir and ritonavir cost, discount & access